Yu Jonathan Yen-Wen sold $705K of IRON

Yu Jonathan Yen-Wen (Chief Operating Officer) sold 9,700 shares of Disc Medicine, Inc. (IRON) at $72.66 ($0.70M total) on 2026-06-22 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Yu Jonathan Yen-Wen
Published Jun 25, 2026, 12:34 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Jun 25, 2026, 12:35 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$IRON
Neutral
high confidence
Mentioned
$IRON
Relevance
4/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$IRONNeutralLow
01

Why it matters

The disclosed sale size (~$705K) is moderate and, because it is 10b5-1 pre-arranged, is typically treated as lower-signal for near-term valuation changes.

02

Market read

Traders may note the insider sale for sentiment monitoring, but the 10b5-1 structure limits actionable inference.

03

What to watch

The article provides no context on total insider holdings beyond the post-sale figure, and 10b5-1 plans are designed to be non-informational.

Relevance 4/10Novelty 3/10Timing: after-hours / latest SEC Form 4 disclosure (filed 2026-06-24)

Background

This is an SEC Form 4 insider transaction for Disc Medicine, Inc. (IRON) by its COO, reported as an open-market sale under a pre-arranged 10b5-1 plan.

Company-level read

Ticker impact

$IRONNeutralHigh confidence
Context

Disc Medicine COO Yu Jonathan Yen-Wen sold 9,700 shares at $72.6593 in an SEC Form 4 filed June 24, 2026.

Expected impact

Limited immediate impact; any effect is likely short-lived and outweighed by broader market factors.

Evidence & confidence

The filing is a Form 4 insider transaction with explicit 10b5-1 pre-arrangement, reducing interpretive signal versus discretionary selling.

Market effects

No clear sector read-through from a single 10b5-1 insider sale.

None indicated.

None indicated.

Counterpoint

Even with 10b5-1, repeated insider sales can coincide with liquidity needs or portfolio rebalancing rather than bearish fundamentals.

Key entities

  • Disc Medicine, Inc.

    Subject of the Form 4 insider transaction; ticker IRON.

  • Yu Jonathan Yen-Wen

    Chief Operating Officer who sold 9,700 shares at $72.6593 under a 10b5-1 plan.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$IRONHighAI 9/10

Disc Medicine Reports Third Quarter 2026 Financial Results and Provides Business Update

Disc Medicine, Inc. (IRON) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Disc Medicine Reports Third Quarter 2026 Financial Results and Provides Business Update • Pivotal Phase 3 APOLLO trial of bitopertin in erythropoietic protoporphyria (EPP) successfully met all primary and secondary endpoints • Bitopertin NDA resubmission planned by e

$IRONHighAI 9/10

Disc Medicine, Inc. (IRON): Results of Operations and Financial Condition

Disc Medicine, Inc. (IRON) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Disc Medicine Announces Proposed $350 Million Public Offering of Common Stock and Pre-Funded Warrants October 19, 2026 WATERTOWN, Mass., Oct. 19, 2026 (GLOBE NEWSWIRE) — Disc Medicine, Inc. (NASDAQ: IRON) (Disc), a clinical-stage biopharmaceutical company focused on

$IRONHighAI 8/10

Why is Disc Medicine stock sliding today?

Disc Medicine (IRON) stock fell 1.0% in pre-market trading after pricing a $450M public offering of 6M shares at $75 each, a discount to recent prices. The offering, with potential for additional shares, may dilute existing holders. Proceeds will fund clinical development and general corporate purposes. Analysts recently raised price targets following positive trial results, but insiders have been net sellers.